Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.85 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.55 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 1/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | PLAT | P00750 | 1/20 | 0.41 |
| ▸ | HPN | P05981 | 1/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14012857 | 0.92 | KDR (1.00) | KDRCHEK1MGLL | |
| SCHEMBL6912138 | 0.90 | KDR (0.89) | KDRCHEK1MGLL | |
| Trifluoroacetic Acid SCHEMBL5078746 | 0.86 | KDR (0.88) | KDRCHEK1MGLL | |
| SCHEMBL5076120 | 0.85 | KDR (0.80) | KDRCHEK1MGLL | |
| SCHEMBL5076073 | 0.84 | KDR (1.00) | KDRCHEK1MGLL | |
| Trifluoroacetic Acid SCHEMBL5076148 | 0.84 | KDR (0.78) | KDRCHEK1MGLL | |
| SCHEMBL5078878 | 0.83 | KDR (1.00) | KDRCHEK1MGLL | |
| SCHEMBL5078739 | 0.80 | KDR (0.78) | KDRCHEK1MGLL | |
| SCHEMBL5078673 | 0.79 | KDR (0.70) | KDRCHEK1 | |
| Trifluoroacetic Acid SCHEMBL5082484 | 0.78 | KDR (0.87) | KDRCHEK1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235826-A1 | Tyrosine kinase ihnibitors | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | claimed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | claimed |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186723-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2005-12-22 | — | — | US | disclosed |
| WO-2003020699-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235826-A1 | Tyrosine kinase ihnibitors | KDR, FLT4, ERBB2 | KDR 1/4885CHEK1 955/4885MGLL 2089/4885 |
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885MGLL 430/4885 |
| US-20050282733-A1 | Differentiation modulating agents and uses therefor | FGF1, FABP4, FGF2 | KDR 1077/4885CHEK1 3154/4885MGLL 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.